FDA OKs Glenmark's Phase II trial for asthma drug

10/29/2007 | Bloomberg1 · India Infoline

Indian drugmaker Glenmark Pharmaceuticals Ltd. announced its partner Forest Laboratories gained FDA approval to carry a Phase II trial in the U.S. for its drug candidate GRC 3886, a PDE4 inhibitor molecule that treats chronic obstructive pulmonary disorder. The agency granted the clearance after Forest Laboratories addressed nonclinical questions concerning the drug.

View Full Article in:

Bloomberg1 · India Infoline

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Various Health Care and IT Positions
Centers for Medicare & Medicaid Services
Baltimore, Bethesda, MD
Counsel II, Legal (Anti-corruption)
Gilead Sciences
Foster City, CA
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Executive Vice President-MyHealth First Network
Greenville Health System
Greenville, SC
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI